Immunohistochemical analysis of tumor tissues from the in vivo models confirmed that TS120-T peptide treatment reduced the cellular levels of TSPYL5, thereby resulting in decreased CD44 and increased PTEN levels (Supplementary Fig. 10). This evidence concerns the gene TSPYL5 and neoplasm.